Respirology Case Reports · Published 2026-07-01 · DOI 10.1002/rcr2.70674
Takayuki Niitsu, Satoshi Tanaka, Moto Yaga, Makoto Yamamoto, Chika Takahashi, Yoshitaka Usui, Daiki Nagira, Tetsuaki Tsuji, Kento Yokota, Satoshi Tobita, Kiyonobu Ueno
ABSTRACT Immune checkpoint inhibitor (ICI) rechallenge may benefit selected patients with NSCLC, but the role of local radiotherapy for oligoprogression and late same‐agent rechallenge remains uncertain. We report a patient with Stage IVA lung adenocarcinoma and a programmed death‐ligand 1 tumour proportion score of ≥ 75% who achieved a durable partial response to first‐line pembrolizumab. After isolated left supraclavicular nodal oligoprogression in 2020, he received salvage radiotherapy and remained off systemic treatment for almost 5 years. In late 2025, multiple new right lower lobe nodules and pleural‐based lesions appeared near the original primary site and enlarged on serial CT, prompting pembrolizumab rechallenge. CT in February 2026 showed a renewed partial response. This case suggests that rechallenge with pembrolizumab may remain reasonable at late relapse in carefully selected patients with durable initial benefit, limited progression controlled locally, a long treatment‐free interval, and good performance status.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →
Niitsu, T., Tanaka, S., Yaga, M., et al. (2026). Renewed Response to Pembrolizumab After Salvage Radiotherapy for Oligoprogression in Advanced NSCLC : A Case Report. Respirology Case Reports. https://doi.org/10.1002/rcr2.70674